Holly White
Family · Appomattox, VANPI 1689063836
Payments from drug & device makers
Across 766 payments — averaging $14.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$2K
- AstraZeneca$1K
- Pfizer$1K
- Lilly USA, LLC$874
- Amgen$534
- plus $3K from 28 others
What the payments were for
- Food & beverage$10,832100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 131 | $1,956 |
| AbbVie | 148 | $1,771 |
| AstraZeneca | 42 | $1,191 |
| Pfizer | 132 | $1,174 |
| Lilly USA, LLC | 47 | $874 |
| Amgen | 44 | $534 |
| Abbott | 21 | $438 |
| Boehringer Ingelheim | 27 | $392 |
| Biohaven Pharmaceuticals, Inc. | 23 | $384 |
| Johnson & Johnson | 22 | $344 |
| Biohaven Pharmaceutical Holding Company Ltd. | 41 | $331 |
| GSK | 13 | $188 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $136 |
| Exact Sciences | 6 | $122 |
| Dexcom, Inc. | 7 | $116 |
| Esperion Therapeutics, Inc. | 6 | $103 |
| Otsuka America Pharmaceutical, Inc. | 6 | $97 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $89 |
| Nestle Healthcare Nutrition Inc. | 4 | $69 |
| Astellas Pharma US Inc | 4 | $57 |
| Merck | 3 | $52 |
| Ironshore Pharmaceuticals Inc. | 2 | $48 |
| Sumitomo Pharma America, Inc. | 3 | $46 |
| Idorsia Pharmaceuticals US Inc | 3 | $43 |
| Bayer | 3 | $40 |
| Amarin Pharma, Inc. | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $38 |
| Phathom Pharmaceuticals, Inc. | 2 | $37 |
| Sanofi Pasteur Inc. | 2 | $26 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Seqirus USA Inc | 1 | $22 |
| Impel Pharmaceuticals Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,832 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 120 | $151,497 |
| MounjaroTirzepatide | 121 | $134,769 |
| EliquisApixaban | 75 | $73,665 |
| Repatha SureclickEvolocumab | 62 | $41,994 |
| JardianceEmpagliflozin | 28 | $41,522 |
| FarxigaDapagliflozin Propanediol | 41 | $39,464 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $26,991 |
| XareltoRivaroxaban | 16 | $26,369 |
| JanuviaSitagliptin Phosphate | 14 | $17,520 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $17,069 |
| EntrestoSacubitril/Valsartan | 21 | $15,657 |
| LinzessLinaclotide | 17 | $14,009 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $12,191 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $11,240 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $11,010 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,956 | $151,497120 claims |
| Lilly USA, LLCMounjaro | $874 | $134,769121 claims |
| PfizerEliquis | $1,174 | $73,66575 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,191 | $56,53369 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $188 | $50,19266 claims |
| Boehringer IngelheimJardiance | $392 | $41,52228 claims |
| MerckJanuvia, Janumet Xr | $52 | $28,76128 claims |
| Johnson & JohnsonXarelto | $344 | $26,36916 claims |
| AbbVieLinzess, Synthroid | $1,771 | $15,37134 claims |
| Astellas Pharma US IncMyrbetriq | $57 | $9,39912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.
Other family in Appomattox
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
- Adam MedlinHampton$67K
- Casey SharpDanville$63K
- Norman JacobowitzManassas$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.